Literature DB >> 15167316

Bioidentical hormone therapy: a review.

Lisa A Boothby1, Paul L Doering, Simon Kipersztok.   

Abstract

OBJECTIVE: The terms "natural" or "bioidentical" hormone therapy (NHT) are used to describe hormone treatment with individually compounded recipes of certain steroids in various dosage forms, including dehydroepiandrosterone, pregnenolone, testosterone, progesterone, estrone, estradiol, and estriol. Based on the results of a person's salivary hormone levels, the final composition of the compounded dosage form is individualized to that specific person. Proponents claim that NHT is better tolerated than manufactured products. This paper is intended to review the concept of NHT and to determine whether there is sufficient scientific evidence to support its use.
DESIGN: A literature search was performed in Medline using the following MeSH terms and key words: drug combinations; progestational hormones; hormone replacement therapy; endometrium; estrogen replacement therapy; climacteric; menopause; estradiol; estrogens; progesterone; drug monitoring; and drug compounding. Current Contents, International Pharmaceutical Abstracts, Cochrane Database of Systematic Reviews, Lexis Nexis, Google, Medscape, MD Consult, and clinicaltrials.gov were searched with key words.
RESULTS: There are a few observational studies and clinical trials comparing conventional hormone therapy with bioidentical hormone therapy. Studies generally lacked adequate study design, including small sample sizes and comparison of inequivalent doses, to prove safety and efficacy. Little evidence was found to support individualized hormone dosing based upon saliva hormone concentrations.
CONCLUSION: Evidence suggests that, although individualized hormonal products may decrease some symptoms of menopause, it seems they have no proven advantage over conventional hormone therapies and their use is not supported by evidence regarding pharmacokinetics, safety, and efficacy.

Entities:  

Mesh:

Year:  2004        PMID: 15167316     DOI: 10.1097/01.gme.0000094356.92081.ef

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  17 in total

Review 1.  Managing the menopause.

Authors:  Helen Roberts
Journal:  BMJ       Date:  2007-04-07

Review 2.  Update on primary ovarian insufficiency.

Authors:  Meghan Hewlett; Shruthi Mahalingaiah
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-12       Impact factor: 3.243

Review 3.  Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause.

Authors:  Morris Notelovitz
Journal:  MedGenMed       Date:  2006-03-28

Review 4.  Bioidentical hormone therapy.

Authors:  Julia A Files; Marcia G Ko; Sandhya Pruthi
Journal:  Mayo Clin Proc       Date:  2011-04-29       Impact factor: 7.616

Review 5.  Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians.

Authors:  Richa Sood; Lynne Shuster; Robin Smith; Ann Vincent; Aminah Jatoi
Journal:  J Am Board Fam Med       Date:  2011 Mar-Apr       Impact factor: 2.657

6.  Progesterone and medroxyprogesterone acetate differentially regulate alpha4 subunit expression of GABA(A) receptors in the CA1 hippocampus of female rats.

Authors:  Karen Pazol; Katharine V Northcutt; Heather B Patisaul; Kim Wallen; Mark E Wilson
Journal:  Physiol Behav       Date:  2009-02-07

7.  Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women.

Authors:  JoAnn V Pinkerton; Nanette Santoro
Journal:  Menopause       Date:  2015-09       Impact factor: 2.953

8.  Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophy.

Authors:  Lisa A Chism
Journal:  Int J Womens Health       Date:  2012-10-12

9.  Bioidentical hormones for menopausal hormone therapy: variation on a theme.

Authors:  Adriane Fugh-Berman; Jenna Bythrow
Journal:  J Gen Intern Med       Date:  2007-03-07       Impact factor: 5.128

Review 10.  Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence.

Authors:  Maria Garefalakis; Martha Hickey
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.